NCT02718911 - A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions

Solid Tumor

Interventions

DRUG

LY3022855

Administered IV

DRUG

Durvalumab

Administered IV

DRUG

Tremelimumab

Administered IV

Trial Locations (14)

2610

GZA St Augustinus, Wilrijk

2650

Universitair Ziekenhuis Antwerpen, Edegem

9000

Universitair Ziekenhuis Gent, Ghent

10016

New York University Medical Center, New York

10032

Columbia University College of Phys & Surgeons, New York

30322

Winship Cancer Center Emory University, Atlanta

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Cancer Center, Nashville

Tennessee Oncology PLLC, Nashville

80218

Sarah Cannon Research Institute at HealthOne, Denver

3109601

Rambam Medical Center, Haifa

5262000

Sheba Medical Center, Ramat Gan

9112001

Hadassah Medical Center, Jerusalem

656 53

Masarykuv Onkology Institute, Brno